FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

Great news for breast cancer patients to educe the amount of radiation.

The U.S. Food and Drug Administration (FDA) approved the non-radioactive tracer Magtrace for the pre-surgical detection of lymph nodes affected by breast cancer.

Magtrace is a non-radioactive liquid marker designed to reveal the route cancer cells are most likely to take when spreading from the primary tumor site. It is a dark solution of tiny iron particles coated with a sugar-like compound (carboxydextran).

Unlike other available tracers, Magtrace can be injected into the breast tissue up to a week before surgery, and can be detected just 20 minutes after administration. This is because of its size: small enough to be quickly absorbed, but big enough to be retained in the lymph nodes.

https://breastcancer-news.com/2018/08/10/fda-approves-non-radioactive-tracer-magtrace-to-ease-lymph-node-biopsy/?utm_source=Breast+Cancer+News&utm_campaign=057c221b05-RSS_MONDAY_EMAIL_CAMPAIGN_US&utm_medium=email&utm_term=0_ea3614260e-057c221b05-72437561